Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Objective The question of sustained remission in SLE has been highlighted recently following data published on the use of ...

Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

Objectives To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods This single-centre, prospective cohort study (January 2012 ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Objectives Neuropsychiatric SLE (NPSLE) lacks evidence-based treatment strategies. This study compared the effectiveness and safety profiles of obinutuzumab (OBZ) and rituximab (RTX) in patients with ...

An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more likely to have adverse kidney outcomes and reduced response to therapy.1 2 ...

Objective To determine whether subclinical brain dysfunction in SLE can be detected by disrupted interhemispheric connectivity and assess its modulation by immunosuppressive regimens. Methods 234 ...

Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune complexes and end-organ damage. Although their role in SLE is ...

Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.